TY - JOUR
T1 - Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin
AU - Buksnys, Titas
AU - Armstrong, Nigel
AU - Worthy, Gill
AU - Sabatschus, Ingo
AU - Boesl, Irmgard
AU - Buchheister, Bettina
AU - Swift, Stephanie L.
AU - Noake, Caro
AU - Carrera, Vanessa Huertas
AU - Ryder, Steve
AU - Shah, Dhwani
AU - Liedgens, Hiltrud
AU - Kleijnen, Jos
N1 - Funding Information:
The project was funded by Grünenthal GmbH, Germany. T.B. and J.K. had ultimate editorial control of the manuscript.
Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/1/2
Y1 - 2020/1/2
N2 - Objective: Neuropathic pain prevalence is estimated between 7% and 10% of the population. International guidelines recommend a variety of drugs at different therapy lines for pain relief. However, side effect profiles, for example, prompted the UK government recently to classify pregabalin and gabapentin as class C drugs. Lidocaine 700 mg medicated plaster (LMP) might be a safer alternative. A systematic review assessed how LMP and pregabalin compared in terms of efficacy and safety. The review focused on pain reduction, quality of life and adverse events in peripheral neuropathic pain (PNP) i.e. post-herpetic neuralgia, diabetic peripheral neuropathy, post-surgical/trauma, or other PNP conditions. Methods: Electronic databases were searched as well as a number of other sources up to November 2018. Sensitive strategies were used, with no restriction by language or publication status. Two independent reviewers screened records and extracted data with consensus determining final decisions. Risk of bias was assessed using the Cochrane Collaboration 2011 checklist for RCTs. Full network meta-analysis was conducted to compare LMP to pregabalin 300/600 mg in terms of pain reduction, quality of life, as well as serious adverse events and selected adverse events. Trials with enriched enrolment design were excluded. Results: Searches retrieved 7,104 records. In total 111 references pertaining to 43 RCTs were included for data extraction. Bayesian network meta-analysis of several pain outcomes showed no clear difference in efficacy between treatments However, LMP was clearly advantageous in terms of dizziness and any adverse event vs. pregabalin 600 mg/day and discontinuations vs. pregabalin 300 mg/day or 600 mg/day, as well as being associated with improved quality of life (albeit in this case based on weak evidence). Conclusions: LMP was found to be similar to pregabalin in reducing pain in all populations but had a better adverse events profile.
AB - Objective: Neuropathic pain prevalence is estimated between 7% and 10% of the population. International guidelines recommend a variety of drugs at different therapy lines for pain relief. However, side effect profiles, for example, prompted the UK government recently to classify pregabalin and gabapentin as class C drugs. Lidocaine 700 mg medicated plaster (LMP) might be a safer alternative. A systematic review assessed how LMP and pregabalin compared in terms of efficacy and safety. The review focused on pain reduction, quality of life and adverse events in peripheral neuropathic pain (PNP) i.e. post-herpetic neuralgia, diabetic peripheral neuropathy, post-surgical/trauma, or other PNP conditions. Methods: Electronic databases were searched as well as a number of other sources up to November 2018. Sensitive strategies were used, with no restriction by language or publication status. Two independent reviewers screened records and extracted data with consensus determining final decisions. Risk of bias was assessed using the Cochrane Collaboration 2011 checklist for RCTs. Full network meta-analysis was conducted to compare LMP to pregabalin 300/600 mg in terms of pain reduction, quality of life, as well as serious adverse events and selected adverse events. Trials with enriched enrolment design were excluded. Results: Searches retrieved 7,104 records. In total 111 references pertaining to 43 RCTs were included for data extraction. Bayesian network meta-analysis of several pain outcomes showed no clear difference in efficacy between treatments However, LMP was clearly advantageous in terms of dizziness and any adverse event vs. pregabalin 600 mg/day and discontinuations vs. pregabalin 300 mg/day or 600 mg/day, as well as being associated with improved quality of life (albeit in this case based on weak evidence). Conclusions: LMP was found to be similar to pregabalin in reducing pain in all populations but had a better adverse events profile.
KW - Neuralgia
KW - lidocaine
KW - pregabalin
KW - systematic review
KW - DIABETIC PERIPHERAL NEUROPATHY
KW - PLACEBO-CONTROLLED TRIAL
KW - RANDOMIZED DOUBLE-BLIND
KW - POSTHERPETIC NEURALGIA
KW - PATCH 5-PERCENT
KW - TOPICAL LIDOCAINE
KW - PAIN RELIEF
KW - INTERVENTIONS
KW - POPULATION
KW - TOLERABILITY
UR - https://tandf.figshare.com/articles/dataset/Systematic_review_and_network_meta-analysis_of_the_efficacy_and_safety_of_lidocaine_700_mg_medicated_plaster_vs_pregabalin/9752795/1
U2 - 10.1080/03007995.2019.1662687
DO - 10.1080/03007995.2019.1662687
M3 - (Systematic) Review article
C2 - 31469302
SN - 0300-7995
VL - 36
SP - 101
EP - 115
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 1
ER -